ASH 2017 | A novel BTK inhibitor BGB-3111: new data presented at ASH 2017
Constantine Tam, MD, from the Peter MacCallum Cancer Centre, Melbourne, Australia tells us about a novel BTK inhibitor, BGB-3111 and how it might compare with existing treatments, such as ibrutinib. Results from three studies on the agent were presented at the ASH 2017 meeting in Atlanta, GA, and Constantine gives us a summary of the data.
